JP Morgan Chase’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-101
Closed -$93 7907
2024
Q1
$93 Hold
101
﹤0.01% 6918
2023
Q4
$207 Hold
101
﹤0.01% 7047
2023
Q3
$368 Buy
101
+100
+10,000% +$433 ﹤0.01% 6764
2023
Q2
$3 Hold
1
﹤0.01% 6850
2023
Q1
$0 Hold
1
﹤0.01% 7551
2022
Q4
$0 Buy
+1
New +$6 ﹤0.01% 7386
2022
Q3
Hold
0
7122
2022
Q2
Sell
-305
Closed -$22.7K 7160
2022
Q1
$43K Buy
305
+65
+27% +$9.49K ﹤0.01% 5855
2021
Q4
$41K Sell
240
-31
-11% -$11.6K ﹤0.01% 6017
2021
Q3
$134K Buy
271
+28
+12% +$13K ﹤0.01% 5424
2021
Q2
$122K Buy
+243
New +$131K ﹤0.01% 5474
2019
Q2
Sell
-80
Closed -$13K 6105
2019
Q1
$13K Sell
80
-3
-4% -$514 ﹤0.01% 5505
2018
Q4
$10K Buy
83
+7
+9% +$1.07K ﹤0.01% 5444
2018
Q3
$12K Buy
76
+22
+41% +$9.2K ﹤0.01% 5489
2018
Q2
$35K Buy
+54
New +$40.4K ﹤0.01% 5195
2017
Q4
Sell
-6
Closed -$1K 5639
2017
Q3
$1K Hold
6
﹤0.01% 4925
2017
Q2
$1K Buy
+6
New +$1.21K ﹤0.01% 4901
2017
Q1
Sell
-38
Closed -$10K 5301
2016
Q4
$10K Buy
+38
New +$9.05K ﹤0.01% 4803

Other funds holding AMPE

JP Morgan Chase's AMPE Position: Q2 2024 in Review

JP Morgan Chase sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q2 2024, closing a stake of 101 shares — an estimated $93 sold.

JP Morgan Chase first reported a position in AMPE in Q4 2016 and held it in 17 quarters. The position peaked at $134K in Q3 2021. 6 funds tracked by Wall St. Rank hold AMPE as of Q2 2024.

  • JP Morgan Chase reported no remaining Ampio Pharmaceuticals Inc. position as of Q2 2024 after selling out during the quarter.
  • JP Morgan Chase sold 101 Ampio Pharmaceuticals Inc. shares in Q2 2024, an estimated $93.
  • JP Morgan Chase first reported a position in Ampio Pharmaceuticals Inc. in Q4 2016 and held it in 17 quarters.
  • JP Morgan Chase's Ampio Pharmaceuticals Inc. position peaked at $134K in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q2 2024.

Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.